Skip to main content
Passa alla visualizzazione normale.


Pari opportunità

SERGIO SIRAGUSA

Bone marrow characteristics predict outcome in a multicenter cohort of primary immune thrombocytopenia patients treated with thrombopoietin analogues

  • Authors: Fattizzo, Bruno; Pasquale, Raffaella; Carpenedo, Monica; Cantoni, Silvia; Auteri, Giuseppe; Gramegna, Doriana; D'Adda, Mariella; Napolitano, Mariasanta; Consonni, Dario; Ruggeri, Marco; Siragusa, Sergio; Rossi, Giuseppe; Vianelli, Nicola; Barcellini, Wilma
  • Publication year: 2019
  • Type: Lettera (Articolo in rivista)
  • OA Link: http://hdl.handle.net/10447/348018

Abstract

It is well established that immune thrombocytopenia (ITP) results from increased immune mediated platelet destruction (anti-platelets antibodies, autoreactive T cells, and reduction of regulatory T cells) along with impaired production in the bone marrow.1 The latter has been attributed to both cellular and humoral mediators that cause suppression of megakaryocyte production and maturation.2 Current standard first line therapy consists of corticosteroids, with or without intravenous Ig, achieving about 70-80% response rate. However, a consistent proportion of patients would relapse after corticosteroid discontinuation or tapering, and requires further therapy. ...